AgingResearch.NewsJoin free

Se-hmpb@ab@cos

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Fudan University and 3 more
  • Animals1

Outcomes

2

Extracellular matrix remodelling

downin animals1

1 study

  1. Se-hmpb@ab@cos inhibits extracellular matrix remodelling.

    “In vivo, Se-HMPB@AB@COS encapsulated with chondroitin sulfate significantly promotes the synthesis of collagen II, inhibits the degradation of extracellular matrix, and reduces inflammatory factors.”

    Animalsin vivo

    Spontaneous hydrogen-releasing nanoenzyme alleviates osteoarthritis via oxidative stress reduction and mitochondrial dysfunction reversal

    Journal of nanobiotechnology11 Oct 2025

More on Extracellular matrix remodelling

Osteoarthritis

downin animals1

1 study

  1. Se-hmpb@ab@cos decreases osteoarthritis.

    “hydrogen-releasing nanozymes (Se-HMPB@AB@COS) that spontaneously release hydrogen gas, effectively treating osteoarthritis through antioxidant, anti-inflammatory, and mitochondrial dysfunction reversal mechanisms.”

    Animalsosteoarthritis

    Spontaneous hydrogen-releasing nanoenzyme alleviates osteoarthritis via oxidative stress reduction and mitochondrial dysfunction reversal

    Journal of nanobiotechnology11 Oct 2025

More on Osteoarthritis

Latest

Related